Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Decera Clinical Education Oncology Podcast

Decera Clinical Education Oncology Podcast artwork

TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies

Oct 29, 202629 minAudioEpisode 278
ShareXLinkedInFacebookWhatsAppEmail

In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including: Current clinical use of Dato-DXd in previously treated EGFR-mutated NSCLC, including evidence from TROPION-Lung01 and TROPION-Lung05 and considerations for treatment sequencing Emerging efficacy data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and the potential role of these agents in earlier lines of therapy Ongoing clinical trials evaluating TROP2 ADCs alone and in combination with immunotherapy, chemotherapy, or EGFR-targeted therapies, including TROPION-Lung07, TROPION-Lung08, TROPION-Lung14, TROPION-Lung15, and AVANZAR Biomarker-guided patient selection, including the potential of the TROP2 QCS-NMR biomarker to identify patients most likely to benefit from Dato-DXd Safety and supportive care considerations, including prevention and management of stomatitis, ocular toxicities, and interstitial lung disease/pneumonitis Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Christine M. Bestvina, MD Associate Professor of Medicine Section of Hematology/Oncology Division of Medicine University of Chicago Medicine Chicago, Illinois Joshua E. Reuss, MD Thoracic Medical Oncologist Director of Thoracic Clinical Research Associate Professor of Medicine Georgetown Lombardi Comprehensive Cancer Center Washington, DC Link to full program: https://bit.ly/4iumiap Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. H3 K27M–Mutated Diffuse Midline Glioma: Bridging Molecular Pathology and Clinical Care

    Nov 13, 202641 minAudio

    In this podcast episode, Craig Horbinski, MD, PhD, and Michael W. Ruff, MD, discuss the evolving diagnosis and management of H3 K27-altered diffuse midline glioma (DMG), emphasizing the importance of molecular testing,...

    Credit the people on this episode

  2. Hematologist On Call: Relapsed/Refractory Mantle Cell Lymphoma Post cBTKi

    Nov 5, 202627 minAudio

    In this podcast episode, Toby A. Eyre, MD, MBChB, and Tycel J. Phillips, MD, FASCO, discuss the evolving treatment landscape of R/R mantle cell lymphoma as covalent BTK inhibitor use further expands into the first-line...

    Credit the people on this episode

  3. Rethinking MZL: From Established Options to T-Cell–Directed Therapies

    Nov 4, 202630 minAudio

    This podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell-engaging approaches for...

    Credit the people on this episode

  4. Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma

    Oct 19, 202624 minAudio

    In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss evolving therapy in newly diagnosed multiple myeloma, including: Selecting quadruplet therapy Optimal use of bortezomib The role of autologous...

    Credit the people on this episode

  5. PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management

    Oct 9, 202627 minAudio

    In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify...

    Credit the people on this episode